Key Metrics 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
ABL Biotechnologies Ltd (526955)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 526955 NSE: Pharmaceuticals & Drugs | Small Cap | ABL Biotechnologies Share Price
BSE Share Price
Not Listed
Not Listed
ABL Biotechnologies Ltd (526955)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 526955 NSE: Pharmaceuticals & Drugs | Small Cap | ABL Biotechnologies Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹1 Cr.
Current Price
₹0
52-Week Low / High
₹1 / 1
TTM EPS
₹-0.2
TTM Sales
₹0 Cr.
Book Value per Share
₹17.3
P/E Ratio
0.00
Industry PE
53.9
Price to Book (P/B)
0.05
Price to Sales (P/S)
0.00
EV/EBITDA
-271.17
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
-1.24%
Return on Capital Employed (ROCE)
-0.56%
Return on Assets (ROA)
-0.40%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Steady versus 3-year growth rate
-100%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
0.60%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹6 Cr.
Equity
₹8.2 Cr.
Face Value
₹10
All Time Low / High
₹0.73 / 222.00
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation ⓘ
| Mar'03 | Mar'04 | Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | Mar'12 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -3.5% | 3.3% | 21.8% | 32.3% | 22.4% | 15.1% | 0.5% | -48% | -1.9% | -0.6% | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 0.2 | 2.6 | 5.8 | 7 | 9.3 | 16.9 | 8.2 | 2.2 | 0 | 0 | 0 |
| Sales YoY Gr. | - | 1,400% | 127.5% | 20.9% | 32.2% | 81.9% | -51.7% | -72.8% | -98.2% | -100% | - |
| Adj EPS ⓘ | -0.4 | 0.2 | 1 | 4.1 | 5.3 | 4.4 | -1.2 | -25.2 | -0.7 | -0.2 | -0.2 |
| YoY Gr. | - | NA | 325% | 302% | 28.3% | -16.9% | -126.8% | NA | NA | NA | - |
| BVPS (₹) ⓘ | 5.6 | 5.5 | 6.2 | 9 | 16.6 | 20.4 | 43.3 | 18.4 | 17.8 | 17.6 | 17.3 |
| Adj Net Profit ⓘ | -0.1 | 0.1 | 0.4 | 1.7 | 2.2 | 1.8 | -1 | -20.6 | -0.6 | -0.2 | -0 |
| Cash Flow from Ops. ⓘ | 0 | 0.6 | 0.6 | -3.6 | 1.8 | -1.7 | 0.8 | -9.6 | -0.5 | -0.1 | - |
| Debt/CF from Ops. ⓘ | 78.5 | 1.8 | 2.8 | -1.4 | 5.7 | -8.6 | 21.3 | -1.7 | -36.2 | -148.9 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -100% | -100% | -100% | -100% | ||||
| Adj EPS ⓘ | NA | -153% | NA | NA | ||||
| BVPSⓘ | 13.6% | 1.2% | -25.9% | -0.9% | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Mar'03 | Mar'04 | Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | Mar'12 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -5.2 | 3.7 | 13.7 | 40 | 24.6 | 14.3 | -3.6 | -69.3 | -3.2 | -1 | -0.9 |
| Op. Profit Mgn % ⓘ | -114 | 7.7 | 11.4 | 17.7 | 18.6 | 19.2 | 4.9 | -899.2 | -1266 | 0 | NAN |
| Net Profit Mgn % ⓘ | -83.6 | 3.9 | 7.2 | 24 | 23.3 | 10.6 | -11.7 | -927.8 | -1425 | 0 | -INF |
| Debt to Equity ⓘ | 0.6 | 0.5 | 0.6 | 1.4 | 1.5 | 1.7 | 0.5 | 1.1 | 1.2 | 1.2 | 0.7 |
| Working Cap Days ⓘ | 310 | 68 | 69 | 182 | 264 | 253 | 646 | 1,613 | 74,662 | 0 | 0 |
| Cash Conv. Cycle ⓘ | -179 | -79 | -71 | -51 | -39 | -19 | -34 | -21 | -9,356 | 0 | 0 |
Valuation of ABL Biotechnologies - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'11 | Mar'12 |
|---|---|---|
| Sales | 0.04 | 0 |
| Operating Expenses ⓘ + | 0.57 | 0.12 |
| Operating Profit ⓘ | -0.53 | -0.12 |
| Operating Profit Margin (%) | -1,266.0% | - |
| Other Income ⓘ + | 0 | 0.01 |
| Interest ⓘ | 0 | 0 |
| Depreciation ⓘ | 0.07 | 0.07 |
| Profit Before Tax ⓘ | -0.60 | -0.18 |
| Tax ⓘ | 0 | 0 |
| Profit After Tax | -0.60 | -0.18 |
| PAT Margin (%) | -1,425.0% | - |
| Adjusted EPS (₹) | -0.7 | -0.2 |
| Dividend Payout Ratio (%) | 0% | 0% |
| PARTICULARS | Mar'11 | Mar'12 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 18.74 | 18.56 | |||||||||
| Debt + | 16.97 | 17.10 | |||||||||
| Minority Interest | 0 | 0 | |||||||||
| Trade Payables | 9.53 | 9.58 | |||||||||
| Others Liabilities ⓘ | 0 | 0 | |||||||||
| Total Liabilities ⓘ | 45.23 | 45.24 | |||||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 34.86 | 34.80 | |||||||||
| CWIP ⓘ | 0 | 0 | |||||||||
| Investments ⓘ | 1.30 | 1.30 | |||||||||
| Inventories | 0 | 0 | |||||||||
| Trade Receivables | 0.32 | 0.32 | |||||||||
| Cash Equivalents | 0.14 | 0.14 | |||||||||
| Others Assets ⓘ | 8.61 | 8.68 | |||||||||
| Total Assets ⓘ | 45.23 | 45.24 | |||||||||
| PARTICULARS | Mar'11 | Mar'12 |
|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 0 | 0 |
| Cash Flow From Investing Activity ⓘ + | 0 | 0 |
| Cash Flow From Financing Activity ⓘ + | 0 | 0 |
| Net Cash Flow ⓘ | 0 | 0 |
| PARTICULARS | Mar'11 | Mar'12 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -4.11 | -1.24 | ||||||||
| ROCE (%) | -1.9 | -0.56 | ||||||||
| Asset Turnover Ratio | 0 | 0 | ||||||||
| PAT to CFO Conversion(x) | N/A | N/A | ||||||||
| Working Capital Days | ||||||||||
| Receivable Days | 2,745.80 | 0 | ||||||||
| Inventory Days | 0 | 0 | ||||||||
| Payable Days | 0 | 0 | ||||||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
ABL Biotechnologies Ltd FAQs
The current trading price of ABL Biotechnologies on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of ABL Biotechnologies stood at ₹0.66 Cr
The latest P/E ratio of ABL Biotechnologies as of 31-Dec-1969 is 0.00.
The latest P/B ratio of ABL Biotechnologies as of 31-Dec-1969 is 0.05.
The 52-week high of ABL Biotechnologies is ₹0.81 and the 52-week low is ₹0.75.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of ABL Biotechnologies is ₹0.00 ( Cr.) .
Data is not available for this company.
No data found
No data found
About ABL Biotechnologies Ltd
ABL Biotechnologies incorporated in 1992, is a pioneer in harnessing the biodiversity of the Indian marine environment. ABL is engagaed in identification and commercial extraction of bio-chemicals, predominantly from microbes, that are used as nutritional, cosmetic, pharmaceutical, and industrial intermediates.
Company’s R&D unit is located at Vishakapatnam that has been recognised by the Department of Scientific and Industrial Research, Ministry of Science and Technology, Government of India.
Company’s microbial metabolites laboratory located at Chennai is focused on evaluating new sources of biochemicals from marine organisms.
Company has collaborated with institutions such as the National Facility for Marine Cyanobacteria, Bharathidasan University, Trichy, the National Institute of Oceanography, The Madras University and the Dr.A.L.M Post Graduate Institute of Medical Sciences, Madras to introduce joint development programmes of advanced research in India.
Company has taken various initiatives such as sale or licensing of technologies, development of biochemical intermediates, conducting research on aquatic biotechnology, product development for therapeutics industry and undertaking contract research. Under contract research company manufactures finished formulations in various formats including soft and hard gelatine capsules, tablets, liquid orals and topical ointments, for various disease states.
ABL has been conducting research on polysaccharides, essential fatty acids, natural pigments, tracers and tags with considerable success. Presently company is focus on developing pharmaceuticals products catering various areas like anti-bacterials and anti-virals, enzymes, bio-molecular materials, bio-monitors and diagnostics, bio-pesticides, bioremediation and aquaculture.
Product portfolio
Company manufactures Beta carotene, which is used as a source of Vitamin A for protection against strokes and cataracts, enhancing the immune system, and preventing photo sensitivity disorders.ABL manufactures Lycopene, an antioxidant carotenoid and pigment that gives characteristic red colour to tomatoes, watermelon, and pink grapefruit.Company developed Lutein, a carotenoid found in fruits and vegetables, including dark green and leafy vegetables, such as spinach and kale, as well as in foods comprising corn and egg yolks.ABL Biotechnologies involves in the production of carotenoid fortified products, including jams, squashes, ketchups and sauces, cooking oils, and chocolates.
Future Plan
ABL Biotechnologies R&D unit plans to strengthen its product portfolio by developing new molecules.
You have 48 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
